RayKnowChina Research Map
Shortlist

Xi'an

Xi'an International Medical Center Hospital

西安国际医学中心医院

Listed for 2 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Xi'an International Medical Center Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Breast cancer乳腺癌11 papers led2 open trials led
  2. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Pancreatic cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Breast cancer

乳腺癌

Led 11 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.06%.

Papers led
11
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 2220232024: 2220242025: 332025

8 hospitals in Xi'an for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
    Phase
    Phase 4
    Started
    2025-10
    Posted
    Registry
    NCT07162259

    Age 18 years to 85 years; women only (registered criteria)

    Led by Xi'an International Medical Center HospitalXi'an

  2. Not yet recruiting
    Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06015113

    Age 18 years to Not stated; women only (registered criteria)

    Led by Xi'an International Medical Center HospitalXi'an

  3. Recruiting
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06757634

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou

  4. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  6. Recruiting
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07173751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesHefei, Jinan, Lanzhou, Linyi, Nanchang, Taiyuan, Wuhan, Xi'an, Zhengzhou

  7. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  8. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led11
  1. A risk model based on signature genes predicts prognosis and associates with tumor immunity, drug sensitivity in breast cancer.2025Cancer biomarkers : section A of Disease markersFree full text
  2. Enabling AI-Generated Content for Gadolinium-Free Contrast-Enhanced Breast Magnetic Resonance Imaging.2025Journal of magnetic resonance imaging : JMRI
  3. Autophagy signaling mediated by non-coding RNAs: Impact on breast cancer progression and treatment.2025Molecular aspects of medicine
  4. Study of the PI3K/Akt/mTOR signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA-MB-231.2024Environmental toxicology
  5. The Efficacy and Safety of Trastuzumab in the Metastatic Breast Cancer.2024Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  6. A case report and literature review on a rare subtype of triple-negative breast cancer in children.2023BMC pediatricsFree full text
  7. Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(-)/PR(+).2023Frontiers in endocrinologyFree full text
  8. Analysis of Prognostic Factors and Construction of Prognostic Models for Invasive Micropapillary Carcinoma of the Breast.2022Computational and mathematical methods in medicineFree full text
  9. Treatment Strategy and Safety of Eribulin in Advanced Breast Cancer.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  10. LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer.2021BioengineeredFree full text
  11. Clinicopathological features and prognosis of male breast cancer.2021The Journal of international medical researchFree full text
All its trials on ClinicalTrials.gov, any status13
  1. Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain MetastasisNot yet recruitingNCT06015113Lead sponsorN/AStart 2023-09
  2. Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast CancerNot yet recruitingNCT07162259Lead (inferred)Phase 4Start 2025-10
  3. Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer PatientsStatus unknownNCT06015126Lead (inferred)N/AStart 2022-10
  4. Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain MetastasisStatus unknownNCT06015100Lead (inferred)N/AStart 2021-02
  5. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingNCT07060807Study sitePhase 3Start 2025-07
  6. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingNCT07173751Study sitePhase 3Start 2025-10
  7. JS207 Combination Therapy in Triple-negative Breast CancerRecruitingNCT07045311Study sitePhase 2Start 2025-09
  8. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingNCT06757634Study sitePhase 3Start 2025-07
  9. A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingNCT06210776Study siteStart 2024-01
  10. A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerRecruitingNCT05851014Study sitePhase 3Start 2022-01
  11. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Study sitePhase 3Start 2023-12
  12. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Study sitePhase 3Start 2022-07
  13. A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerActive, not recruitingNCT03975647Study sitePhase 3Start 2019-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Xi'an for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [Excerpt from the 2022 American Association for the Study of Liver Diseases clinical practice guideline: management of primary sclerosing cholangitis and cholangiocarcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

西安国际医学中心医院

Xi'an International Medical Center Hospital

西安

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data